IPP Bureau
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
By IPP Bureau - August 10, 2024
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
32 projects completed under PLI Scheme for promotion of domestic manufacturing of Critical KSMs/DIs and APIs
By IPP Bureau - August 10, 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
AstraZeneca Pharma India achieves 31% revenue growth in Q1 FY25
By IPP Bureau - August 09, 2024
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Atul Bioscience received EIR from USFDA for Ambernath facility
By IPP Bureau - August 09, 2024
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
CCRUM organises webinar on quality standards for healthcare delivery system in Unani Medicine
By IPP Bureau - August 08, 2024
Nearly 200 participants from 50 Unani Academia and Council participated
Jagsonpal Pharmaceuticals Q1 FY25 revenues at Rs. 61.4 Crores, 41% growth over Q4 FY24
By IPP Bureau - August 08, 2024
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
By IPP Bureau - August 08, 2024
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
By IPP Bureau - August 08, 2024
Expect the international business including CDMO business to pick-up in the second half of the financial year
Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses
By IPP Bureau - August 08, 2024
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
By IPP Bureau - August 07, 2024
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
By IPP Bureau - August 07, 2024
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Gland Pharma posts 16% revenue growth in Q1 FY25
By IPP Bureau - August 07, 2024
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza upgrades clinical manufacturing services at Bend site to include bottling and labeling capabilities
By IPP Bureau - August 07, 2024
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Daiichi Sankyo and Merck enter into global agreement for MK-6070
By IPP Bureau - August 07, 2024
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
